Propranolol
As of the edition of 20 October 2026, Propranolol is a small molecule: marketed, first approved in 1966 (ES); acts on ADRB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Inderal
- First approved
- 1 February 1966 (ES)
- Approvals on record
- 27 in 5 regions
- Holder of the most recent approval
- Maruho; 9 holders in all
- Registered trials
- 225, 35 stopped early
- Disease areas
- Cancer; Mental health; Heart and blood vessels; Nervous system; Digestive system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 companies on route B because of this drug.
Companies on route B for this drug
In the product4 companies are on route B because of Propranolol.
See the 4 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 45 | 20 | 10 | 2 |
| Phase 1 | 40 | 24 | 10 | 3 |
| Phase 2 | 84 | 28 | 20 | 18 |
| Phase 3 | 25 | 12 | 5 | 6 |
| Phase 4 | 31 | 16 | 5 | 6 |
| All trials | 225 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Later holder | 1983 to now |
| Baxter Healthcare | Acquired holder | 2003 to now |
| Pierre Fabre | Applicant | 2014 to now |
| Maruho | Applicant | 2016 to now |
| ANI Pharmaceuticals | Acquired holder | 2016 to now |
| Eton Pharmaceuticals | Acquired holder | 2026 to now |
| AstraZeneca | Later holder |